文献速递前列腺增生与排尿功能障碍

锯叶棕提取物治疗中国良性前列腺增生患者的疗效与安全性:多中心、随机、双盲、安慰剂对照试验

Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
PubMed 文献 · Urology · 2019-03-14

这项多中心随机双盲安慰剂对照试验纳入来自19家机构的354例下尿路症状/良性前列腺增生(LUTS/BPH)患者,按1:1随机接受锯叶棕提取物(320 mg)或安慰剂治疗24周。结果显示锯叶棕提取物组在最大尿流率、国际前列腺症状评分、储尿期与排尿期症状评分、生活质量评分、四条目男性性功能问卷评分及国际勃起功能指数评分方面较安慰剂组均有统计学显著改善(P<.05),两组不良事件发生率分别为3/159(1.89%)和2/169(1.18%)。

要点

  • 锯叶棕提取物320 mg治疗24周在LUTS/BPH患者中疗效与安全性优于安慰剂。
  • 主要疗效指标最大尿流率和国际前列腺症状评分较安慰剂组有统计学显著改善(P<.05)。
  • 锯叶棕提取物组不良事件3/159(1.89%),安慰剂组2/169(1.18%)。

核心结论

  • 锯叶棕提取物在目标LUTS/BPH人群中有效、安全、耐受良好,临床和统计学上优于安慰剂。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,纳入来自19家机构的354例LUTS/BPH患者。
  • 参与者按1:1随机分配至锯叶棕提取物(320 mg)组或安慰剂组,治疗24周。

主要发现

  • 锯叶棕提取物组较安慰剂组在最大尿流率、国际前列腺症状评分、储尿期症状评分、排尿期症状评分、生活质量评分、四条目男性性功能问卷评分及国际勃起功能指数评分方面均有统计学显著改善(P<.05)。
  • 安慰剂组169例中2例(1.18%)发生1次或以上不良事件,锯叶棕提取物组159例中3例(1.89%)发生1次或以上不良事件。

关键数值与推荐

  • 主要疗效参数为国际前列腺症状评分和最大尿流率从基线至各次评估的变化。
  • 次要疗效参数包括储尿期症状与排尿期症状评分的改善、前列腺体积、排尿频率及总前列腺特异性抗原水平。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of Serenoa repens among patients with benign prostatic hyperplasia (lower urinary tract symptoms/benign prostatic hyperplasia [LUTS/BPH]) in China. METHODS: We conducted a double blind, placebo-controlled study of 354 patients with LUTS/BPH from 19 institutions, to evaluate the efficacy and safety of Serenoa repens. Participants were randomly assigned (1:1) into the Serenoa repens extract (320 mg) or placebo groups for 24 weeks. Primary efficacy parameters were changes in International Prostate Symptom Score and peak urinary flow from baseline to each assessment. Secondary efficacy parameters included improvement of storage symptom and voiding symptom scores, prostate volume, urinary frequency, and total prostate-specific antigen level. Other parameters assessed were quality of life score, a four-item male sexual function questionnaire score, and International Index of Erectile Function score across the consecutive double-blind visits. RESULTS: Statistically significant improvement in the peak urinary flow, International Prostate Symptom Score, scores of storage symptoms and voiding symptoms, quality of life score, four-item male sexual function questionnaire score, and International Index of Erectile Function score were observed in the Serenoa repens extract group compared with those in the placebo group (P <.05). Two (1.18%) of 169 patients in the placebo group and 3 (1.89) of 159 patients in the Serenoa repens extract group experienced 1 or more adverse events. CONCLUSION: The Serenoa repens extract was effective, safe, well-tolerated, and clinically and statistically superior to placebo in the target LUTS/BPH population.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Ye Z, Huang J, Zhou L, et al. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology. 2019. PMID: 30880074. doi:10.1016/j.urology.2019.02.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。